Persistent erythema multiforme treated with thalidomide.
Erythema multiforme is a common self-limited disorder that predominantly affects younger individuals. It is characterized by typical iris or target lesions on the skin and mucous membranes. Three clinical subgroups of erythema multiforme have been identified: classical erythema multiforme, recurrent erythema multiforme, and persistent erythema multiforme. By definition, persistent erythema multiforme is characterized by the occurrence of continuous typical and atypical lesions without interruption. We report a 15-year-old boy who developed persistent erythema multiforme for 6 months and responded to treatment with thalidomide.
Chen
Chia-Wei
CW
Department of Dermatology, Show Chwan Memorial Hospital, Taiwan, Republic of China.
Tsai
Tsen-Fang
TF
Chen
Yu-Fu
YF
Hung
Chih-Ming
CM
D000293:Adolescent; D004892:Erythema Multiforme / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D012867:Skin / Q000473:pathology*; D013792:Thalidomide / Q000009:adverse effects / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D013792:Thalidomide